The association between cardiovascular disease and acute renal failure (ARF) and acute-on-chronic renal failure is less well defi ned. In the cardiac intensive care unit (CICU), the presence of ARF imparts a signifi cant mortality. The predominant aetiology of ARF in the CICU relates to hypotension, although other causes are certainly involved too, and both contrast nephropathy and cholesterol embolisation may be associated with percutaneous coronary intervention. Despite the availability of renal replacement therapies, preventative measures remain the most important element of management. Specifi c therapy includes management of the patient's volume status, vasoactive medication and renal replacement therapy in the way of dialysis. In the setting of acute renal failure, both patient and renal outcome is improved with the early involvement of a nephrological service.
INTRODUCTION
There is a strong and well-established association between cardiovascular disease and chronic kidney disease (CKD); however, the association between cardiovascular disease and acute renal failure (ARF) and acute-on-chronic renal failure is less well defi ned. What is clear is that, in the cardiac intensive care unit (CICU), the presence of ARF imparts a signifi cant mortality, where up to 50% may die. Furthermore, the common association of diabetes and cardiovascular disease is further complicated by the concomitant risk of kidney disease. As the population ages, with its increasing comorbidities and acuity of illness, and the epidemic of cardiovascular disease continues to rise, we are likely to see more patients developing ARF in the CICU setting. Prevention and management of this development are of paramount importance to improve overall outcome of these patients and to practise cost-effective medicine.
Elderly patients are more likely to have comorbidities and more likely to develop renal failure, in association with percutaneous and surgical coronary interventions.
With judicious preventative strategies and aggressive management, survival rates have improved, especially when adjusted for illness severity.
(1)
DEFINITION OF ACUTE RENAL FAILURE
A widely accepted and systematic defi nition of ARF has been lacking, which has led to signifi cant confusion both clinically and in the medical literature. In 2004, the Acute Dialysis Quality Initiative (ADQI) group published the RIFLE (Risk, Injury, Failure, Loss, End-stage kidney disease) classifi cation of ARF, based on changes from the patient's baseline either in serum creatinine level or glomerular fi ltration rate (GFR), urine output (UO), or both. (2) Although not universally accepted, we feel this provides an appropriate defi nition.
The RIFLE classifi cation of ARF is as follows: 
AETIOLOGIES OF ARF IN THE CICU
Considering the common association between acute cardiac disease, hypotension and renal failure, it is not suprising that the prevailing aetiology of ARF in the CICU relates to hypotension. Other pathogenic mechanisms are involved, as outlined in (Figure 1 ).
Volume depletion, hypotension and cardiogenic shock
Reduced cardiac output (CO) due to hypovolemia or cardiac dysfunction (acute MI, CHF, and arrhythmia) diminishes renal perfusion both directly and indirectly. Cardiogenic shock is a progressive state of hypotension (systolic blood pressure < 90 mm Hg) lasting at least 30 minutes, which leads to systemic hypoperfusion and is generally more common in patients with ST-segment elevation myocardial infarction than in patients with other acute coronary syndromes. 
The history in some patients often includes a decrease in fl uid intake, 
Percutaneous coronary intervention
The two common causes of renal failure following PCI are contrast nephropathy (CN) and cholesterol embolisation (CE).
Cholesterol embolisation syndrome is a systemic disease caused by distal
showering of cholesterol crystals after angiography, major vessel surgery, or thrombolysis. It is relatively rare following coronary intervention, and those patients with an elevated CRP pre-procedure may be at greater risk for its development. More than 60% of patients suffering from this syndrome develop renal insuffi ciency. (9) Part of the diffi culty in making the diagnosis relates to the time interval (typically one to four weeks but occasionally several months) between intervention and disease onset, which tends to obscure the causative link. In the context of renal disease, this delay in onset and subsequent progressive deterioration in renal function can help to distinguish cholesterol embolism from contrast nephropathy (see below). Given our inability to reverse the condition, early diagnosis is crucial if further episodes of cholesterol emboli are to be prevented. Statin therapy may stabilise plaques and a highly conservative approach, avoiding anticoagulation, angiography and vascular surgery, may produce the best outcome. Renal failure often progresses to dependence on dialysis. (10) Importantly, acute renal failure that requires dialysis after percutaneous coronary interventions is associated with very high in-hospital and 1-year mortality rates and a dramatic increase in hospital resource utilization. (11) PCI and contrast nephropathy
Although defi nitions may vary, a commonly accepted and applied defi nition of contrast nephropathy is a > 25% increase in serum creatinine level that occurs within 48 hours of contrast exposure. (12) Once CN occurs, kidney function may remain depressed for 1-3 weeks depending on the severity of the insult, but returns to normal or near normal in most cases. (13) The presence of predisposing risk factors ( (2) , NO)
The most important risk factors seem to be the presence of preexisting kidney insuffi ciency, diabetes mellitus, fl uid depletion, the elderly and the volume of contrast used. (14) The use of nonionic agents (15) appears to lower the incidence of CN and this has been confi rmed in animal models. (16) Recommendations for management of contrast nephropathy depend on the underlying kidney function. (17) In those patients with normal serum creatinine, adequate hydration is all that is necessary. Although serum creatinine levels may be normal, diabetics, elderly patients and those with reduced muscle mass may have a normal U&E although their creatinine clearance may be reduced, thereby imparting a risk for CN. In this setting, a calculated creatinine clearance would be more appropriate. In those with moderate kidney insuffi ciency (creatinine 150mmol/l-250mmol/l, creatinine clearance <50ml/min) intravenous volume administration with saline 0.45% or 0.9% for 12 hours before and 6 hours after the procedure. Recent data suggests that isotonic sodium bicarbonate may be more protective, although this has not been substantiated. (18) Iso-osmolar contrast agents with judicious dose limitation may also reduce the risk of CN and repeat procedures should be delayed as long as possible. Acetylcysteine 600mg bid on the day before and on the day of the procedure is advocated, though the benefi t of this agent is controversial. Severe kidney insuffi ciency (creatinine >250mmol/l, creatinine <30ml/min) imparts a risk of irreversible kidney failure despite the abovementioned preventative measures. Such a risk should be discussed with the patient prior to the intervention and the need for the intervention should be debated.
Although the overall incidence of ARF after PCI is low, acute renal insuffi ciency after PCI is a strong and independent predictor of longterm mortality in patients who survive for 30 days after the procedure. (19) Diabetic patients with baseline serum creatinine values <170 umol/l are at higher risk than nondiabetic patients, whereas all patients with a serum creatinine >170 umol/l are at high risk for ARF.
Sepsis
Although sepsis is a common cause of acute renal failure in the general intensive care unit, it is an unusual occurrence in the coronary care unit.
Its presence as a primary disease, however, may precipitate an acute cardiac event. (21) The classical pathogenic mechanism of septic acute renal failure revolves around haemodynamic disease where fl uid resuscitation aims to prevent and restore renal function. Recently, however, Wan et al. reviewed the subject and suggested that, indeed, acute tubular apoptosis may underlie the renal effects of sepsis, and management of precipitants may improve renal outcome. (22) Animal studies suggest that protein C has anti-infl ammatory and anti-apoptotic functions, which are reduced in acute sepsis especially when acute renal failure is induced. In these studies treatment of septic animals with activated protein C improved renal function, suggesting anti-apoptosis. (23) Mechanical ventilation causes pulmonary biotrauma, with a resultant pulmonary infl ammatory reaction that may generate systemic release of infl ammatory mediators, which have apoptotic effects, especially in the kidney. In theory, low volume mechanical ventilation may reduce such mediators and their renal side-effects. (24) Intensive insulin therapy improves outcome in the ICU patient where strict glucose control seems to improve dysregulated apoptosis, which may aid in recovery from renal failure. (25, 26) Appropriate antibiotic usage adjusted for renal function and/or dialysis is equally important in controlling sepsis and its consequences. Statins are used by millions of people worldwide and only rarely cause severe side effects, the most sinister of which is rhabdomyolysis induced ARF. To this end, the American Heart Association lists a group of patients most at risk of severe myopathy and these include: advanced age, multisystem disease (e.g. chronic renal failure, especially if caused by diabetes), perioperative periods, multiple medications (especially gemfi brozil, and cytochrome P3A4 interactors cyclosporine, itraconazole and ketoconazole, macrolide antibiotics, erythromycin and clarithromycin, HIV protease inhibitors in those on statins using this metabolic pathway) and alcohol abuse. (28) Since the timing of this toxicity is unpredictable, routine screening is not recommended. Therefore, patients should be made aware of muscle symptoms and promptly discontinue the statin when these occur while awaiting laboratory (creatine kinase) assessment.
MANAGEMENT STRATEGIES
Despite the availability of renal replacement therapies, preventative measures remain the most important element of management. Table 1 outlines such therapies, although predicting who may be at risk for ARF, especially from contrast (Table 2) , could circumvent its development.
Patients with acute cardiac events often have a preceding history of hypertension. This results in the autoregulatory level of renal blood fl ow being set at a higher level and renal blood fl ow decreases signifi cantly when the mean arterial blood pressure falls below 80mmHg, severely compromising renal perfusion and function. (29) These patients are at particular risk of hypoperfusion.
Reversal of a compromised haemodynamic state with inotropic support, appropriate fl uid resuscitation and primary coronary intervention seems prudent in acutely compromised cardiac patients. noradrenalin. Noradrenalin will raise mean arterial pressure at the expense of cardiac output and thus cardiac output should be adequate before its initiation. Dobutamine (beta-agonist) will increase cardiac output but will also vasodilate and thus venous return may need augmentation with a fl uid bolus. Adrenaline has both alpha and beta effects and is used in resuscitation and severe hypotension. One must remember that long-term usage leads to tissue ischemia, the resultant acidosis of which may reduce effectiveness of other inotropic agents.
Importantly, whilst a renal vasodilator dose of dopamine (1.5 to 2.5 ug/kg/min) may stimulate urine volume, it does not improve GFR, shorten the duration of ARF, or decrease dialysis requirements. (31) In addition, dopamine may induce signifi cant arrhythmia and possibly intestinal ischemia.
Many patients with ARF will recover renal function within days and not require renal replacement therapy (RRT). However, if the duration of ARF is prolonged, or if hyperkalemia, extracellular volume overload, refractory acidosis or uremic symptoms (serositis, encephalopathy, Regardless of the particular RRT selected, the clinician must ensure an adequate dose of dialysis. Currently, no measure of dialysis adequacy allows comparison of different RRTs applied to patients with ARF. (33) Peritoneal dialysis (PD) plays a relatively minor role as an RRT in the CICU. Nevertheless, it offers several advantages including simplicity, hemodynamic stability and freedom from anticoagulation. Automated cyclers easily accomplish the exchange of dialysate; however, even with frequent dialysate exchanges and very hypertonic dialysate, PD clearance of solute and UF rates are limited. In addition, the intraperitoneal volume of dialysate can compromise respiration, and glucose loads and protein losses can be excessive. Therefore, PD appears better suited for the less catabolic, less uremic, and relatively normovolemic patient.
CONCLUSION
The development of ARF in the cardiac ICU patient portends an ominous outcome. Assessment and reduction of risk factors for ARF, thereby preventing its occurrence, is appropriate in all patients admitted and treated. When ARF does occur, early involvement of the kidney team (consultation and renal replacement) is likely to improve outcome in such patients. (34) 
